Table 3.
Genotype frequencies of polymorphisms of EGF gene in ESRD patients undergone kidney transplantation and controls.
| SNP | Genotype | Control | KT | Models | OR (95% CI) | p Value |
|---|---|---|---|---|---|---|
| n (%) | n (%) | |||||
| rs11568835 | G/G | 195 (67.5%) | 222 (64%) | Codominant1 | 1.13 (0.80–1.59) | .50 |
| A/G | 85 (29.4%) | 109 (31.4%) | Codominant2 | 1.57 (0.68–3.61) | .30 | |
| A/A | 9 (3.1%) | 16 (4.6%) | Dominant | 1.15 (0.83–1.60) | .41 | |
| Recessive | 1.44 (0.62–3.31) | .39 | ||||
| Log-additive | 1.15 (0.87–1.53) | .32 | ||||
| rs11568943 | G/G | 193 (66.8%) | 220 (63.4%) | Codominant1 | 1.13 (0.81–1.59) | .48 |
| A/G | 86 (29.8%) | 111 (32%) | Codominant2 | 1.40 (0.62–3.17) | .41 | |
| A/A | 10 (3.5%) | 16 (4.6%) | Dominant | 1.17 (0.84–1.63) | .35 | |
| Recessive | 1.34 (0.60–3.00) | .48 | ||||
| Log-additive | 1.16 (0.88–1.53) | .3 | ||||
| rs2237051 | A/A | 131 (45.3%) | 169 (48.7%) | Codominant1 | 0.85 (0.61–1.17) | .32 |
| A/G | 132 (45.7%) | 144 (41.5%) | Codominant2 | 0.01 (0.58–1.77) | .96 | |
| G/G | 26 (9%) | 34 (9.8%) | Dominant | 0.86 (0.63–1.18) | .35 | |
| Recessive | 1.10 (0.64–1.88) | .74 | ||||
| Log-additive | 0.93 (0.73–1.19) | .58 | ||||
| rs11569017 | A/A | 184 (63.9%) | 216 (62.2%) | Codominant1 | 0.96 (0.69–1.33) | .80 |
| T/A | 104 (36.1%) | 117 (33.7%) | Codominant2 | NA (0.00–NA) | <.0001 | |
| T/T | 0 (0%) | 14 (4%) | Dominant | 1.09 (0.78–1.50) | .62 | |
| Recessive | NA (0.00–NA) | <.0001 | ||||
| Log-additive | 1.24 (0.92–1.67) | .16 | ||||
| rs3756261 | A/A | 188 (65%) | 217 (62.7%) | Codominant1 | 1.10 (0.78–1.53) | .62 |
| A/G | 89 (30.8%) | 112 (32.4%) | Codominant2 | 1.23 (0.57–2.64) | .60 | |
| G/G | 12 (4.2%) | 17 (4.9%) | Dominant | 1.12 (0.81–1.55) | .50 | |
| Recessive | 1.19 (0.56–2.53) | .66 | ||||
| Log-additive | 1.11 (0.84–1.45) | .47 |
EGF: epidermal growth factor; ESRD: end stage renal disease; KT: kidney transplantation.